国产美女一区二区,亚洲精品欧美一区二区,久久久精品国产亚洲亚洲,国内精品自线一区二区三区2023,日本国产一区二区三区,久久久久免费影院,羞羞漫画网18久久app,亚洲精品乱码久久久主播,777电影网,国产精品久久久情品

  Recently, Dr. Regina Fritsche Danielson, Senior Vice President and Head of Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), AstraZeneca BioPharmaceuticals R&D, led a delegation to visit Cholesgen to discuss their early-stage drug development collaboration. To date, the joint collaboration efforts in early-stage drug development have progressed smoothly and are delivering to plan. During the visit, AstraZeneca recognized the team for the project’s execution, as well as Cholesgen’s R&D capabilities and professional expertise and both parties reviewed the existing collaboration outcomes and discussed potential for further opportunities.

 近日，阿斯利康全球高級副總裁，心血管、腎病及代謝疾病早期研發(fā)負責人Regina Fritsche Danielson博士率團訪問珂闌醫(yī)藥，就雙方在早期藥物開發(fā)領域的合作展開交流。目前雙方在早期藥物開發(fā)方面的聯(lián)合合作進展順利，按計劃有序推進。

  訪問期間，阿斯利康對項目執(zhí)行情況、珂闌醫(yī)藥的研發(fā)實力與專業(yè)能力給予了認可；雙方共同回顧了現(xiàn)有合作成果，并探討了未來進一步深化合作的潛在機會。